Roquinimex

Drugbox
IUPAC_name = 4-hydroxy-"N",1-dimethyl-2-oxo-"N"-
phenyl-1,2-dihydroquinoline-3-carboxamide

---

CAS_number = 84088-42-6
ATC_prefix = L03
ATC_suffix = AX02
PubChem = 55197
DrugBank =
C=18|H=16|N=2|O=3
molecular_weight = 308.331 g/mol
bioavailability =
protein_bound =
metabolism =
elimination_half-life = 26-42 hours
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration =

Roquinimex (Linomide) is a quinoline derivative immunostimulant which increases NK cell activity and macrophage cytotoxicity. It also inhibits angiogenesis and reduces the secretion of TNF alpha.

Roquinimex has been investigated as a treatment for some cancers (including as adjuvant therapy after bone marrow transplantation in acute leukemia) and autoimmune diseases, such as multiple sclerosis and recent-onset type I diabetes. Several trials have been terminated due to serious cardiovascular toxicity.